ArticleIranian journal of basic medical sciences2020
Evaluation of antibacterial activity of enterocin A-colicin E1 fusion peptide.
Article in Iranian journal of basic medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Investigation of the Antibacterial Effectiveness of Hybrid Recombinant Bacteriocins Circular Enterocin and Pyocin L1 Derived from Pseudomonas aeruginosa and Enterococcus faecalis.Biochemical genetics · 2026Article
- Genomic safety assessment and metabolic modulation by Enterococcus faecium 140,623, a probiotic strain from lactasin tablets: implications for obesity management.World journal of microbiology & biotechnology · 2026Article
- Gene profile of virulence, antimicrobial resistance and action of enterocins in Campylobacter species isolated from broiler carcasses.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Insight into the Probiogenomic Potential ofFoods (Basel, Switzerland) · 2024Article
- Shotgun Metagenomics Reveals Taxonomic and Functional Patterns of the Microbiome Associated with Barbour's Seahorse (Hippocampus barbouri).Marine biotechnology (New York, N.Y.) · 2024Article
- Turbidimetric bioassays: A solution to antimicrobial activity detection in asymptomatic bacteriuria isolates against uropathogenic Escherichia coli.MicrobiologyOpen · 2024Article
- Structure, Function, and Physicochemical Properties of Pore-forming Antimicrobial Peptides.Current pharmaceutical biotechnology · 2024Review
- Molecular and Genetic Characterization of ColicinogenicFoods (Basel, Switzerland) · 2023Article
- Article
- Enterocin: Promising Biopreservative Produced byMicroorganisms · 2022Review
- Structural and functional insights into colicin: a new paradigm in drug discovery.Archives of microbiology · 2021Review
- Anticancer Effect of Enterocin A-Colicin E1 Fusion Peptide on the Gastric Cancer Cell.Probiotics and antimicrobial proteins · 2021Article
- Prevalence of bacteriocin genes inIranian journal of basic medical sciences · 2021Article
- Phage vB_PaeS-PAJD-1 Rescues Murine Mastitis Infected With Multidrug-ResistantFrontiers in cellular and infection microbiology · 2021Article
- Effect ofFrontiers in microbiology · 2021Article
- Methyltransferase as Antibiotics Against Foodborne Pathogens: AnFrontiers in genetics · 2021Article
- Article
- Designing and cloning of fusion protein CpsA-CpsC-L-ACAN.Medical journal, Armed Forces IndiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesBacterial resistance to most common antibiotics is a harbinger of the requirement to find novel anti-infective, antimicrobials agents, and increase innovative strategies to struggle them. Numerous bacteria produce small peptides with antimicrobial activities called bacteriocin. This study aimed to investigate the antibacterial properties of the fusion protein of Enterocin A and Colicin E1 modified against pathogens. MATERIALS AND
methodsAnalysis of recombinant bacteriocin Enterocin A and Colicin E1 (ent A-col E1) was performed to assay the stability and antibacterial activity of this fusion protein. The pET-22b vector was employed to express the coding sequence of the ent A-col E1 peptide in
resultsThe suggested recombinant peptide had good antibacterial activity against both Gram-negative and Gram-positive pathogens. It has also good stability at various temperatures, pH levels, and salt concentrations.
conclusionBecause bacteriocins are harmless compounds, they can be recommended as therapeutic or preventive supplements to control pathogens. According to the obtained results, the ent A-col E1 peptide can serve as an efficient antibacterial compound to treat or prevent bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.